223 related articles for article (PubMed ID: 2306514)
21. The N-terminal epidermal growth factor-like domain in factor IX and factor X represents an important recognition motif for binding to tissue factor.
Zhong D; Bajaj MS; Schmidt AE; Bajaj SP
J Biol Chem; 2002 Feb; 277(5):3622-31. PubMed ID: 11723140
[TBL] [Abstract][Full Text] [Related]
22. Cooperative activation of human factor IX by the human extrinsic pathway of blood coagulation.
Lawson JH; Mann KG
J Biol Chem; 1991 Jun; 266(17):11317-27. PubMed ID: 2040636
[TBL] [Abstract][Full Text] [Related]
23. The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis.
Hoffman M; Monroe DM
Semin Hematol; 2001 Oct; 38(4 Suppl 12):6-9. PubMed ID: 11735103
[TBL] [Abstract][Full Text] [Related]
24. Phospholipid regulates the activation of factor X by tissue factor/factor VIIa (TF/VIIa) via substrate and product interactions.
Hathcock JJ; Rusinova E; Gentry RD; Andree H; Nemerson Y
Biochemistry; 2005 Jun; 44(22):8187-97. PubMed ID: 15924438
[TBL] [Abstract][Full Text] [Related]
25. Hemophilia as a defect of the tissue factor pathway of blood coagulation: effect of factors VIII and IX on factor X activation in a continuous-flow reactor.
Repke D; Gemmell CH; Guha A; Turitto VT; Broze GJ; Nemerson Y
Proc Natl Acad Sci U S A; 1990 Oct; 87(19):7623-7. PubMed ID: 2120704
[TBL] [Abstract][Full Text] [Related]
26. Substitution of the Gla domain in factor X with that of protein C impairs its interaction with factor VIIa/tissue factor: lack of comparable effect by similar substitution in factor IX.
Ndonwi M; Broze GJ; Agah S; Schmidt AE; Bajaj SP
J Biol Chem; 2007 May; 282(21):15632-44. PubMed ID: 17387172
[TBL] [Abstract][Full Text] [Related]
27. Pharmacological concentrations of recombinant factor VIIa restore hemostasis independent of tissue factor in antibody-induced hemophilia mice.
Keshava S; Sundaram J; Rajulapati A; Pendurthi UR; Rao LV
J Thromb Haemost; 2016 Mar; 14(3):546-50. PubMed ID: 26727350
[TBL] [Abstract][Full Text] [Related]
28. The role of tissue factor and factor VIIa in hemostasis.
Mackman N
Anesth Analg; 2009 May; 108(5):1447-52. PubMed ID: 19372318
[TBL] [Abstract][Full Text] [Related]
29. Mechanism by which recombinant factor VIIa shortens the aPTT: activation of factor X in the absence of tissue factor.
Telgt DS; Macik BG; McCord DM; Monroe DM; Roberts HR
Thromb Res; 1989 Dec; 56(5):603-9. PubMed ID: 2626745
[TBL] [Abstract][Full Text] [Related]
30. An unusual antibody that blocks tissue factor/factor VIIa function by inhibiting cleavage only of macromolecular substrates.
Fiore MM; Neuenschwander PF; Morrissey JH
Blood; 1992 Dec; 80(12):3127-34. PubMed ID: 1467519
[TBL] [Abstract][Full Text] [Related]
31. Inhibition of tissue factor-factor VIIa-catalyzed factor X activation by factor Xa-tissue factor pathway inhibitor. A rotating disc study on the effect of phospholipid membrane composition.
Salemink I; Franssen J; Willems GM; Hemker HC; Lindhout T
J Biol Chem; 1999 Oct; 274(40):28225-32. PubMed ID: 10497177
[TBL] [Abstract][Full Text] [Related]
32. Direct Amplification of Tissue Factor:Factor VIIa Procoagulant Activity by Bile Acids Drives Intrahepatic Coagulation.
Baker KS; Kopec AK; Pant A; Poole LG; Cline-Fedewa H; Ivkovich D; Olyaee M; Woolbright BL; Miszta A; Jaeschke H; Wolberg AS; Luyendyk JP
Arterioscler Thromb Vasc Biol; 2019 Oct; 39(10):2038-2048. PubMed ID: 31412737
[TBL] [Abstract][Full Text] [Related]
33. New insights into how blood clots: implications for the use of APTT and PT as coagulation screening tests and in monitoring of anticoagulant therapy.
Bajaj SP; Joist JH
Semin Thromb Hemost; 1999; 25(4):407-18. PubMed ID: 10548073
[TBL] [Abstract][Full Text] [Related]
34. Beating tissue factor at its own game: Design and properties of a soluble tissue factor-independent coagulation factor VIIa.
Sorensen AB; Tuneew I; Svensson LA; Persson E; Østergaard H; Overgaard MT; Olsen OH; Gandhi PS
J Biol Chem; 2020 Jan; 295(2):517-528. PubMed ID: 31801825
[TBL] [Abstract][Full Text] [Related]
35. The effect of temperature and pH on the activity of factor VIIa: implications for the efficacy of high-dose factor VIIa in hypothermic and acidotic patients.
Meng ZH; Wolberg AS; Monroe DM; Hoffman M
J Trauma; 2003 Nov; 55(5):886-91. PubMed ID: 14608161
[TBL] [Abstract][Full Text] [Related]
36. Enzymatically oxidized phospholipids restore thrombin generation in coagulation factor deficiencies.
Slatter DA; Percy CL; Allen-Redpath K; Gajsiewicz JM; Brooks NJ; Clayton A; Tyrrell VJ; Rosas M; Lauder SN; Watson A; Dul M; Garcia-Diaz Y; Aldrovandi M; Heurich M; Hall J; Morrissey JH; Lacroix-Desmazes S; Delignat S; Jenkins PV; Collins PW; O'Donnell VB
JCI Insight; 2018 Mar; 3(6):. PubMed ID: 29563336
[TBL] [Abstract][Full Text] [Related]
37. A soluble tissue factor mutant is a selective anticoagulant and antithrombotic agent.
Kelley RF; Refino CJ; O'Connell MP; Modi N; Sehl P; Lowe D; Pater C; Bunting S
Blood; 1997 May; 89(9):3219-27. PubMed ID: 9129026
[TBL] [Abstract][Full Text] [Related]
38. Vascular endothelial growth factor production by fibroblasts in response to factor VIIa binding to tissue factor involves thrombin and factor Xa.
Ollivier V; Chabbat J; Herbert JM; Hakim J; de Prost D
Arterioscler Thromb Vasc Biol; 2000 May; 20(5):1374-81. PubMed ID: 10807756
[TBL] [Abstract][Full Text] [Related]
39. Protein disulfide isomerase has no stimulatory chaperone effect on factor X activation by factor VIIa-soluble tissue factor.
Persson E
Thromb Res; 2008; 123(1):171-6. PubMed ID: 18550154
[TBL] [Abstract][Full Text] [Related]
40. Structural modulation of factor VIIa by full-length tissue factor (TF
Prasad R; Sen P
J Biomol Struct Dyn; 2018 Feb; 36(3):621-633. PubMed ID: 28150568
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
